Engineered Trimeric CD70 Proteins for Persistent T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-T cell therapies face challenges in providing prolonged anti-cancer activity in vivo due to insufficient activation signals and inadequate persistence of T cells, leading to failure in killing targeted cancer cells and maintaining therapeutic effects.
Innovation Solution
Engineered trimeric CD70 proteins are used during ex vivo T cell manufacturing to enhance CD27 signaling, resulting in expanded T cell populations that proliferate more, persist longer, and selectively expand naïve and memory subsets, thereby improving therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If monovalent or bivalent approaches are used to stimulate CD27 during cell manufacturing, then the activation process is simpler, but the agonistic signaling is insufficient and T cell activation is not effective
Solution Approach 1:
The patent changes the valency parameter of the CD70 ligand from monovalent/bivalent to multivalent (trimeric/tetrameric configurations). This parameter change enables the ligand to simultaneously engage multiple CD27 receptors on T cells, generating sufficient clustering and signaling strength for effective activation, while maintaining operational simplicity through the use of engineered multimeric proteins.
Solution Approach 2:
The patent creates composite ligand structures by combining multiple CD70 binding domains with multimerization domains (such as Fc regions or self-assembling peptide structures). These composite multimeric ligands integrate the functions of antigen binding and receptor clustering, achieving effective T cell activation through enhanced signal transduction.
2Ease of manufacture
If conventional T cell activation methods are used, then the manufacturing process is straightforward, but T cells do not proliferate sufficiently or persist in vivo for sufficient periods
Solution Approach 1:
The patent applies preliminary action by incorporating multimeric CD70 ligands into the T cell manufacturing process before final product formulation. This preliminary activation and expansion phase with enhanced signaling ensures that the resulting CAR-T cells have improved persistence capabilities in vivo, addressing the durability issue before administration to patients.
Solution Approach 2:
The patent changes the signaling intensity parameter during the manufacturing process by using multimeric CD70 ligands that provide stronger and more sustained activation signals. This parameter change during production results in T cell populations with enhanced in vivo persistence without requiring changes to the overall manufacturing workflow.
3Productivity
If CAR-T cells are administered to patients, then cancer cell destruction occurs, but T cells fail to provide prolonged anti-cancer activity due to insufficient activation signals
Solution Approach 1:
The patent implements preliminary action by optimizing T cell activation and expansion during the manufacturing phase using multimeric CD70 ligands. This preliminary enhancement of activation signals ensures that the administered CAR-T cells possess improved functionality and persistence, enabling them to provide prolonged anti-cancer activity after infusion without requiring additional in vivo stimulation.
4Reliability
If T cells receive strong activation signals, then proliferation and persistence are enhanced, but the activation process becomes more complex
Solution Approach 1:
The patent changes the structural parameter of the activating ligand from simple monovalent/bivalent forms to engineered multimeric structures. This parameter change inherently provides stronger activation signals through multivalent binding and receptor clustering, achieving enhanced T cell proliferation and persistence without adding operational complexity to the activation process.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The engineered trimeric CD70 proteins increase T cell proliferation and persistence, enhance memory cell expansion, and improve therapeutic effects by increasing engraftment and tumor cell targeting, with up to 50% more proliferation and 1000-fold longer persistence in vivo compared to conventional methods.
Implementation Method 1
Binding of CD70 to CD27 is important in the priming phase of T cell activation, in the acquisition of effector functions, and in the formation of long-lived T cell memory
Implementation Method 2
This interaction of multi-trimer-based clustering is essential for agonistic signaling. Because of these clustering requirements for activation of CD27 agonistic signaling, many attempts to stimulate CD27 during cell manufacturing with monovalent and bivalent approaches have not been sufficiently effective.
Data Source
AI summary
Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.